Amber McKenery

Amber McKenery

Auto-generated profile, based on publicly available information

Amber McKenery

Department of Cancer Genetics and Genomics Roswell Park Comprehensive Cancer Center 14263 Buffalo NY USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M. L. Ebos
John M. L. Ebos
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly. This includes the induction of molecular markers associated with senescence, a form of cellular aging that typically involves growth arrest. We have shown that VEGFR TKIs can hijack these aging programs by transiently inducting senescence markers (SMs) in tumor cells to activate senescence-associated secretory programs that fuel drug resistance. Here we show that these same senescence-mimicking (“senomimetic”) VEGFR TKI effects drive an enhanced immunogenic signaling that, in turn, can alter tumor response to immunotherapy. By using a live cell sorting method to detect β-galactosidase, a commonly used SM, we found that subpopulations of SM-expressing (SM+) tumor cells have heightened IFN signaling and increased expression of IFN-stimulated genes (ISGs). These ISGs increase under the control of the STimulator of the INterferon Gene (STING) signaling pathway, which we found could be directly activated by several VEGFR TKIs. TKI-induced SM+ cells could stimulate or suppress CD8 T-cell activation depending on host–tumor cell contact while tumors grown from SM+ cells were more sensitive to PDL1 inhibition in vivo, suggesting that offsetting immune-suppressive functions of SM+ cells can improve TKI efficacy overall. Our findings may explain why some (but not all) VEGFR TKIs improve outcomes when combined with immunotherapy and suggest that exploiting senomimetic drug side effects may help identify TKIs that uniquely “prime” tumors for enhanced sensitivity to PDL1-targeted agents.

4 September 2024
Verified
Other
Open access
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M.L. Ebos
John M.L. Ebos
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly. This includes the induction of molecular markers associated with senescence, a form of cellular aging that typically involves growth arrest. We have shown that VEGFR TKIs can hijack these aging programs by transiently inducting senescence markers (SMs) in tumor cells to activate senescence-associated secretory programs that fuel drug resistance. Here we show that these same senescence-mimicking (“senomimetic”) VEGFR TKI effects drive an enhanced immunogenic signaling that, in turn, can alter tumor response to immunotherapy. By using a live cell sorting method to detect β-galactosidase, a commonly used SM, we found that subpopulations of SM-expressing (SM+) tumor cells have heightened IFN signaling and increased expression of IFN-stimulated genes (ISGs). These ISGs increase under the control of the STimulator of the INterferon Gene (STING) signaling pathway, which we found could be directly activated by several VEGFR TKIs. TKI-induced SM+ cells could stimulate or suppress CD8 T-cell activation depending on host–tumor cell contact while tumors grown from SM+ cells were more sensitive to PDL1 inhibition in vivo, suggesting that offsetting immune-suppressive functions of SM+ cells can improve TKI efficacy overall. Our findings may explain why some (but not all) VEGFR TKIs improve outcomes when combined with immunotherapy and suggest that exploiting senomimetic drug side effects may help identify TKIs that uniquely “prime” tumors for enhanced sensitivity to PDL1-targeted agents.

4 September 2024
Verified
Other
Open access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M.L. Ebos
John M.L. Ebos
Figure S1: Extended data for Fig 1 - Enriched IFN signaling in SM+ tumor cells after VEGFR TKI treatment. (A) In vivo derivation of 4T1AxR lung metastasis taken from mice after surgical resection of orthotopically implanted 4T1 cells and following Ax treatment (100mg/kg/day). Described in 7. (B) Proliferation analysis of 4T1 cells after treatment with multiple VEGFR TKIs. IC50 values indicated in red. (MTS assay; n = 3-4) (C) In vivo derivation of a Ca-resistant mouse breast tumor cell line EMT6 (EMT6CaR) and vehicle-treated control (EMT6M) taken from lung metastasis of Balb/c mice after orthotopic implantation of EMT6 and following Ca (30mg/kg/day) or vehicle treatment. (D-E) EMT6CaR cells showed increases (compared to EMT6M controls) in D) SM expression (by flow cytometry; n=6) and E) ISG expression (by qRT-PCR; n=3). (F) Proliferation analysis of EMT6M cells after Ca and Ax treatment to choose optimal dosing. IC50 values indicated in red. (MTS assay; n = 3-4) (G-I) SM expression after Ax or Ca treatment in (F) EMT6M, (G) RENCA, and (H) LM2-4 cells (flow cytometry; n=3-6). (J-L) ISG expression after Ca treatment in (I) EMT6M, (J) 4T1, and (K) LM2-4 cells (qRT-PCR; n=3). (M) ISG expression after Ax treatment in EMT6M cells (qRT-PCR; n=3). Parental (P), Axitinib (Ax), Cabozantinib (Ca), Short-term (ST), Vehicle (Veh), Fold Change (FC); Interferon-stimulated genes (ISGs); 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG); Standard deviation (SD); Drug concentration for Ax (0.5µM for F and L; 2µM for G and K) and Ca (2µM for F, G, I and J; 5µM for H and K); #, indicates experiment terminated. Quantitative data is shown as mean ± SD; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

4 September 2024
Verified
Other
Open access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M.L. Ebos
John M.L. Ebos
Figure S1: Extended data for Fig 1 - Enriched IFN signaling in SM+ tumor cells after VEGFR TKI treatment. (A) In vivo derivation of 4T1AxR lung metastasis taken from mice after surgical resection of orthotopically implanted 4T1 cells and following Ax treatment (100mg/kg/day). Described in 7. (B) Proliferation analysis of 4T1 cells after treatment with multiple VEGFR TKIs. IC50 values indicated in red. (MTS assay; n = 3-4) (C) In vivo derivation of a Ca-resistant mouse breast tumor cell line EMT6 (EMT6CaR) and vehicle-treated control (EMT6M) taken from lung metastasis of Balb/c mice after orthotopic implantation of EMT6 and following Ca (30mg/kg/day) or vehicle treatment. (D-E) EMT6CaR cells showed increases (compared to EMT6M controls) in D) SM expression (by flow cytometry; n=6) and E) ISG expression (by qRT-PCR; n=3). (F) Proliferation analysis of EMT6M cells after Ca and Ax treatment to choose optimal dosing. IC50 values indicated in red. (MTS assay; n = 3-4) (G-I) SM expression after Ax or Ca treatment in (F) EMT6M, (G) RENCA, and (H) LM2-4 cells (flow cytometry; n=3-6). (J-L) ISG expression after Ca treatment in (I) EMT6M, (J) 4T1, and (K) LM2-4 cells (qRT-PCR; n=3). (M) ISG expression after Ax treatment in EMT6M cells (qRT-PCR; n=3). Parental (P), Axitinib (Ax), Cabozantinib (Ca), Short-term (ST), Vehicle (Veh), Fold Change (FC); Interferon-stimulated genes (ISGs); 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG); Standard deviation (SD); Drug concentration for Ax (0.5µM for F and L; 2µM for G and K) and Ca (2µM for F, G, I and J; 5µM for H and K); #, indicates experiment terminated. Quantitative data is shown as mean ± SD; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

4 September 2024
Verified
Other
Open access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M.L. Ebos
John M.L. Ebos
Figure S2: SM+ and SM- signature genes in 4T1 variants used to generate the SM+ T score. (A) SM+ signature gene expression using log2CPMs in 4T1P, 4T1AxR, 4T1AxR SM+ and 4T1AxR SM- cells. (B) SM- cell signature gene expression using log2CPMs in 4T1P, 4T1AxR, 4T1AxR SM+ and 4T1AxR SM- cells. Parental (P); Axitinib-resistant (AxR); Senescence-marker (SM); Counts per million (CPM)

4 September 2024
Verified
Other
Open access
PDF file
MDMelissa Dolan
Melissa Dolan
YSYuhao Shi
Yuhao Shi
MMMichalis Mastri
Michalis Mastri
MLMark Long
Mark Long
AMAmber McKenery
Amber McKenery
JEJohn M.L. Ebos
John M.L. Ebos
Supplemental Results, Key Resources Table, Supplementary Data Files